Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
0.7690
+0.0144 (1.91%)
At close: May 12, 2025, 4:00 PM
0.7690
0.00 (0.00%)
After-hours: May 12, 2025, 6:49 PM EDT
Palisade Bio Employees
Palisade Bio had 8 employees as of December 31, 2024. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,804,750
Market Cap
3.38M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8 | -1 | -11.11% |
| Dec 31, 2023 | 9 | -3 | -25.00% |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PALI News
- 6 days ago - Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases - GlobeNewsWire
- 11 days ago - Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit - GlobeNewsWire
- 4 weeks ago - Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108 - GlobeNewsWire
- 2 months ago - Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108 - GlobeNewsWire
- 2 months ago - Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025 - GlobeNewsWire
- 2 months ago - Palisade Bio Participates in Virtual Investor “What This Means” Segment - GlobeNewsWire
- 2 months ago - Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) - GlobeNewsWire
- 2 months ago - Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewsWire